Abstract

Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple-negative breast cancer (TNBC)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
359P - Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast cancer (TNBC)
A Noske ... W Weichert
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 30
A Noske, et. al.A Noske ... W Weichert
01 Oct 2019
305O - Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
L.A Emens ... S Loi
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 30
L.A Emens, et. al.L.A Emens ... S Loi
01 Oct 2019
LBA20 - Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
H.S Rugo ... L.A Emens
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 30
H.S Rugo, et. al.H.S Rugo ... L.A Emens
01 Oct 2019
1519P - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
M Sebastian ... M Thomas
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 30
M Sebastian, et. al.M Sebastian ... M Thomas
01 Oct 2019
View more papers